Bluejay Diagnostics, Inc. (BJDX)

NASDAQ: BJDX · Real-Time Price · USD
1.600
0.00 (0.00%)
At close: Jun 24, 2025, 4:00 PM
1.610
+0.010 (0.63%)
After-hours: Jun 24, 2025, 7:53 PM EDT
0.00%
Market Cap 2.39M
Revenue (ttm) n/a
Net Income (ttm) -20.48M
Shares Out 1.49M
EPS (ttm) -63.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 62,811
Open 1.600
Previous Close 1.600
Day's Range 1.580 - 1.625
52-Week Range 1.460 - 188.505
Beta 0.38
Analysts n/a
Price Target n/a
Earnings Date Aug 13, 2025

About BJDX

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 10, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol BJDX
Full Company Profile

Financial Performance

Financial Statements

News

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for...

21 days ago - GlobeNewsWire

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.

2 months ago - GlobeNewsWire

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfo...

2 months ago - GlobeNewsWire

Bluejay Diagnostics Announces Reverse Stock Split

ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

7 months ago - GlobeNewsWire

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

1 year ago - GlobeNewsWire

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and ar...

1 year ago - GlobeNewsWire

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

1 year ago - GlobeNewsWire

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

1 year ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.

1 year ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests...

1 year ago - GlobeNewsWire

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

ACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

1 year ago - GlobeNewsWire

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

ACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

2 years ago - GlobeNewsWire

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) --  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...

2 years ago - GlobeNewsWire

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

ACTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symp...

2 years ago - GlobeNewsWire

Bluejay Diagnostics Reports 2022 Financial Results

ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Sy...

2 years ago - GlobeNewsWire

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

ACTON, Mass. and WEST WARWICK, R.I., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed ...

2 years ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests...

2 years ago - GlobeNewsWire

Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: BSGMSTSS
3 years ago - Benzinga

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-pat...

3 years ago - GlobeNewsWire

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

Webinar to be held Thursday, August 25th @ 11:00am EDT Webinar to be held Thursday, August 25th @ 11:00am EDT

3 years ago - GlobeNewsWire

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Demonstrated 98% NPV 1 to Identify COVID-19 Patients at Risk for Severe Illness

3 years ago - GlobeNewsWire

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-p...

3 years ago - GlobeNewsWire

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-pat...

3 years ago - GlobeNewsWire

Why Bluejay Diagnostics Shares Are Surging Higher Today

Shares of small-cap penny stock Bluejay Diagnostics, Inc. (NASDAQ: BJDX) are trading higher after the company announced that the FDA has agreed to consider its plan to pursue a De Novo submission for ...

3 years ago - Benzinga

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, ra...

3 years ago - GlobeNewsWire